Effect of low-dose oral etoposide on serum CA-125 in patients with advanced epithelial ovarian cancer

RS deJong, LS Hofstra, PHB Willemse, HWA deBruijn, EGE deVries, NH Mulder, J. Boonstra

Research output: Contribution to journalArticleAcademicpeer-review

18 Citations (Scopus)

Abstract

The effect of oral etoposide on CA-125 serum levels was evaluated in 17 patients with epithelial ovarian cancer and progressive disease during, or relapsing after, prior chemotherapy. Only three patients had measurable lesions at extraperitoneal sites. Five had no measurable lesions. The oral etoposide dose was 50 mg b.d. for 7 days every 3 weeks, escalating to 10 or 14 days and continued until clinical progression. CA-125 after 4 courses was compared to baseline (CA-125 ratio). The rate of change of CA-125 (s, slope of the exponential regression curve) during the first 4 courses was compared to s over a similar period before treatment. One patient had a clinical partial response. Two other patients had a biochemical response (CA-125 ratio

Original languageEnglish
Pages (from-to)197-201
Number of pages5
JournalGynecologic Oncology
Volume66
Issue number2
Publication statusPublished - Aug-1997

Keywords

  • HALF-LIFE
  • PHASE-II
  • SURVIVAL
  • DISEASE
  • TAXOL

Cite this